Delving into the Latest Updates on Shanghai Yuyao Biotechnology Co., Ltd. with Synapse

Overview

Basic Info

Introduction

Shanghai Yuyao Biotechnology Co., Ltd. was established in April 13, 2020, Their main business includes technology services, technology consulting, technology transfers, and technology promotions. They focus on utilizing artificial intelligence and modern new drug creation technologies to address significant clinical drug needs, and are committed to enhancing human health levels. The company also established close cooperative relationships with top domestic institutions and research organizations, collectively promoting the integration of production, education, and research.

Tags

Neoplasms

Digestive System Disorders

Immune System Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	6
Endocrinology and Metabolic Disease	1
Hemic and Lymphatic Diseases	1
Immune System Diseases	1

Top 5 Drug Type	Count

Small molecule drug	6

Top 5 Target	Count

STAT3(Signal transducer and activator of transcription 3)	1
EP4(Prostanoid EP4 receptor)	1

剂量递增阶段主要目的：评价YY201在晚期实体瘤和复发难治性恶性血液肿瘤患者中的安全性和耐受性，观察可能出现的剂量限制性毒性（DLT）及最大耐受剂量（MTD）和/或 II 期临床试验推荐剂量（RP2D）。次要目的：评价YY201在晚期实体瘤和复发难治性恶性血液肿瘤患者中的药代动力学（PK）特征和初步疗效。探索性目的：探索生物标志物与疗效之间的关系。剂量扩展阶段主要目的：评价YY201在标准治疗失败或无标准治疗的实体瘤（包括三阴性乳腺癌、胰腺癌、头颈部鳞癌等）和复发难治性恶性血液肿瘤（包括急性髓系白血病）以及外周T细胞淋巴瘤患者中的安全性和耐受性，以及初步疗效。次要目的：评价YY201在标准治疗失败或无标准治疗的实体瘤（包括三阴性乳腺癌、胰腺癌、头颈部鳞癌等）和复发难治性恶性血液肿瘤（包括急性髓系白血病）以及外周 T 细胞淋巴瘤患者中的PK特征。探索性目的：探索生物标志物与疗效之间的关系。

[Translation]

The main purpose of the dose escalation phase is to evaluate the safety and tolerability of YY201 in patients with advanced solid tumors and relapsed and refractory hematological malignancies, and to observe possible dose-limiting toxicity (DLT) and the maximum tolerated dose (MTD) and/or the recommended dose (RP2D) for Phase II clinical trials. Secondary purpose: to evaluate the pharmacokinetic (PK) characteristics and preliminary efficacy of YY201 in patients with advanced solid tumors and relapsed and refractory hematological malignancies. Exploratory purpose: to explore the relationship between biomarkers and efficacy. The main purpose of the dose expansion phase is to evaluate the safety and tolerability of YY201, as well as the preliminary efficacy, in patients with solid tumors (including triple-negative breast cancer, pancreatic cancer, head and neck squamous cell carcinoma, etc.) and relapsed and refractory hematological malignancies (including acute myeloid leukemia) and peripheral T-cell lymphoma who have failed standard treatment or have no standard treatment. Secondary purpose: To evaluate the PK characteristics of YY201 in patients with solid tumors (including triple-negative breast cancer, pancreatic cancer, head and neck squamous cell carcinoma, etc.) and relapsed and refractory hematological malignancies (including acute myeloid leukemia) and peripheral T-cell lymphoma who have failed or have no standard treatment. Exploratory purpose: To explore the relationship between biomarkers and efficacy.

Start Date15 Nov 2023

Sponsor / Collaborator

Shanghai Yuyao Biotechnology Co., Ltd.

NCT06225856 / RecruitingPhase 1

An Open-Label, Multicenter, Phase I Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of YY201 in Patients With Advanced Solid Tumors and Hematological Malignancies

This is a multicenter, open-label, phase I clinical study of YY201 in the patients with relapsed/refractory lymphomas and relapsed/refractory large granular lymphocytic leukemia who failed or cannot tolerate standard treatment.

Start Date26 Oct 2023

Sponsor / Collaborator

Shanghai Yuyao Biotechnology Co., Ltd.

CTR20221559 / Active, not recruitingPhase 1

评价YY001治疗晚期实体瘤患者的安全性、耐受性、药代动力学特征的开放性I期临床研究

[Translation] An open-label phase I clinical study to evaluate the safety, tolerability, and pharmacokinetic characteristics of YY001 in the treatment of patients with advanced solid tumors

主要目的：评价YY001治疗晚期实体瘤患者的安全性、耐受性，观察可能出现的剂量限制性毒性（DLT）及最大耐受剂量（MTD）或推荐II期临床给药剂量（RP2D）。次要目的：评价YY001在晚期实体瘤患者中的药代动力学（PK）特征和抗肿瘤活性。探索性目的：初步评价生物标志物与疗效之间的关系。

[Translation]

Primary objective: To evaluate the safety and tolerability of YY001 in the treatment of patients with advanced solid tumors, and to observe possible dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) or recommended phase II clinical dose (RP2D). Secondary objective: To evaluate the pharmacokinetic (PK) characteristics and antitumor activity of YY001 in patients with advanced solid tumors. Exploratory objective: To preliminarily evaluate the relationship between biomarkers and efficacy.

Start Date14 Jul 2022

Sponsor / Collaborator

Shanghai Yuyao Biotechnology Co., Ltd.

100 Clinical Results associated with Shanghai Yuyao Biotechnology Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Shanghai Yuyao Biotechnology Co., Ltd.

Login to view more data

100 Deals associated with Shanghai Yuyao Biotechnology Co., Ltd.

Login to view more data

100 Translational Medicine associated with Shanghai Yuyao Biotechnology Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 25 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

4

1

Phase 1 Clinical

Phase 2 Clinical

1

Other

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

YY-001 ( EP4 )	Stomach Cancer More	Phase 2
YY-201 (Shanghai Yuyao) ( STAT3 )	T-Cell Lymphoma More	Phase 1
YY-601	Neoplasms More	Preclinical
YY-401	Neoplasms More	Preclinical
YY-501	Neoplasms More	Preclinical